Adjuvant treatment with osimertinib substantially reduces the risk for central nervous system recurrence among patients with resected stage IB–IIIA EGFR-mutated non-small-cell lung cancer, shows an analysis of phase 3 study data.
Patients with completely resected stage IIIA N2 non-small-cell lung cancer do not benefit from postoperative radiotherapy, show the results of the phase 3 Lung ART trial presented at the ESMO Virtual Congress 2020.
The phase 3 CheckMate 9ER trial has demonstrated significantly improved outcomes with the combination of nivolumab and cabozantinib versus sunitinib in treatment-naïve patients with advanced renal cell carcinoma.
Christopher Sweeney reports on the IPATential150 trial demonstrating the potential of combining the AKT inhibitor ipatasertib with abiraterone in metastatic castration-resistant prostate cancer patients with PTEN loss.
Nadia Harbeck presents the IMpassion031 study showing improved pathological complete responses with the addition of atezolizumab to neoadjuvant chemotherapy in patients with early-stage triple-negative breast cancer.
Further findings from the TROPHY-U-01 trial indicate that the Trop-2-directed antibody–drug conjugate sacituzumab govitecan has efficacy in heavily pretreated patients with metastatic urothelial cancer.